162 related articles for article (PubMed ID: 37006974)
21. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
22. Real-life comparison of posaconazole versus fluconazole for primary antifungal prophylaxis during remission-induction chemotherapy for acute leukemia.
Dufresne SF; Bergeron J; Beauchemin S; Abou Chakra CN; Vadnais B; Bouchard P; Labbé AC; Laverdière M
J Assoc Med Microbiol Infect Dis Can; 2023 Mar; 8(1):18-28. PubMed ID: 37008582
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.
Kang KW; Lee BH; Jeon MJ; Yu ES; Sik Kim D; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Ther Adv Hematol; 2020; 11():2040620720966882. PubMed ID: 35154623
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation.
Belling M; Kanate AS; Shillingburg A; Lu X; Wen S; Shah N; Craig M; Cumpston A
Leuk Res Treatment; 2017; 2017():3460892. PubMed ID: 28695013
[TBL] [Abstract][Full Text] [Related]
25. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
[TBL] [Abstract][Full Text] [Related]
26. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Michallet M; Sobh M; Morisset S; Deloire A; Raffoux E; de Botton S; Caillot D; Chantepie S; Girault S; Berthon C; Bertoli S; Lepretre S; Leguay T; Castaigne S; Marolleau JP; Pautas C; Malfuson JV; Veyn N; Braun T; Gastaud L; Suarez F; Schmidt A; Gressin R; Bonmati C; Celli-Lebras K; El-Hamri M; Ribaud P; Dombret H; Thomas X; Bergeron A
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):311-318. PubMed ID: 34895843
[TBL] [Abstract][Full Text] [Related]
27. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
28. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of target attainment of oral posaconazole suspension in immunocompromised children.
Lai T; Alffenaar JW; Kesson A; Bandodkar S; Roberts JA
J Antimicrob Chemother; 2020 Mar; 75(3):726-729. PubMed ID: 31855264
[TBL] [Abstract][Full Text] [Related]
30. A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India.
George B; Menon H; Bhurani D; Damodar S; Apte S; Seth T; Sharma A; Shyam R; Malhotra P; Easow J; Lakshmi KM; Agrawal N; Sengar M; Nataraj KS; Ahmed R; Sharma S; Khadwal A; Prakash G; Abraham A; Devasia A; Korula A; Mathews V
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):97-103. PubMed ID: 32158091
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
32. Invasive fungal infection following venetoclax and posaconazole co-administration.
Reynolds G; Urbancic KF; Fong CY; Trubiano JA
Br J Haematol; 2023 Nov; 203(4):593-598. PubMed ID: 37731068
[TBL] [Abstract][Full Text] [Related]
33. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
[TBL] [Abstract][Full Text] [Related]
34. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
35. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy: An Observational Study in Resource Limited Settings.
Bansal D; Seth T; Kumar R; Saxena R; Mishra P; Xess I
Indian J Hematol Blood Transfus; 2018 Jul; 34(3):460-465. PubMed ID: 30127553
[TBL] [Abstract][Full Text] [Related]
37. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
Döring M; Cabanillas Stanchi KM; Klinker H; Eikemeier M; Feucht J; Blaeschke F; Schwarze CP; Ebinger M; Feuchtinger T; Handgretinger R; Heinz WJ
Med Mycol; 2017 Jun; 55(4):375-384. PubMed ID: 27703016
[TBL] [Abstract][Full Text] [Related]
38. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]